Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
about
In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid LeukemiaThe development of bispecific antibodies and their applications in tumor immune escape.Targeting CD157 in AML using a novel, Fc-engineered antibody construct.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma.Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemiaPotent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.Recent developments in immunotherapy of acute myeloid leukemia.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.Acute myeloid leukemia targets for bispecific antibodies.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.PD-1/PD-L1 inhibitors in haematological malignancies: update 2017.Programmed Death Ligand 1 (PD-L1)-targeted TRAIL combines PD-L1-mediated checkpoint inhibition with TRAIL-mediated apoptosis induction.Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomabCD3xPDL1 bi-specific T cell engager (BiTE) simultaneously activates T cells and NKT cells, kills PDL1+ tumor cells, and extends the survival of tumor-bearing humanized mice.SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Blinatumomab (Blincyto): lessons learned from the bispecific t-cell engager (BiTE) in acute lymphocytic leukemia (ALL).PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?Higher PD-1 expression concurrent with exhausted CD8+ T cells in patients with de novo acute myeloid leukemia.Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia.Clinical Development of PD-1 Blockade in Hematologic Malignancies.Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia.Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer TherapyImmune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic optionDual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cellsCD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cellsDevelopment of a Target cell-Biologics-Effector cell (TBE) complex-based cell killing model to characterize target cell depletion by T cell redirecting bispecific agents
P2860
Q28554677-F93A0374-7CE8-4114-8FD5-8A3076BD181BQ33630292-3CAD1EFA-75C0-4592-B9A7-B76FBA8501DAQ33829283-279B9021-E011-4321-A85D-4E345CB2B5B9Q34548319-DEE7D6F4-16EF-4DDB-AE1F-AEE3D745BA51Q36370054-530E69E0-1D31-41D0-ABA9-37DEF5F927A5Q36946572-29AC936C-323E-4B5B-AC93-2F814F32ED9BQ37706213-72AB5A50-5F04-44CF-99C2-3D84C89AA766Q38661895-027A7ACA-CCAC-41E8-8CA8-5D39FD1E2985Q38670099-4AFBC2C2-7B56-4D3B-85FD-AB1869B97858Q38714704-A89D3383-7CB9-40E3-B545-0D8D7E837CB1Q38727986-F693F715-A0EC-4564-BAE9-C05AAD72E885Q38814436-1F5A6594-DA27-4105-AA4D-0E3EE9993865Q39117761-340AA7D6-91A5-479E-91B5-AD91DCC2AEFCQ39175665-B0B240E0-F1DF-4EF7-9D12-3FB327B6D0B5Q39420466-4AAB61D9-5D38-40F4-BA3D-235BDF8E20A9Q40994131-2BD62660-81F4-4CA9-9865-211B3C9BD992Q41048538-DEEA5AFE-8F95-4E47-88FC-60D055195920Q41708676-B6B9A271-8E4D-4994-A027-CFDFE4194E31Q42315730-62220AB6-6ADE-42BC-BA13-7F59F0B8C2CBQ42660142-8F205EE4-4E5C-445E-B1D4-770465AEE843Q46474224-B9BD1279-F158-47F6-B3C7-81D9BB6E7FF8Q47120629-13B70030-9690-4948-B08F-7550C85985C9Q47151143-B54F2D55-B0D8-469D-BA88-6C5063874B9CQ47818563-D6013926-F33B-41FA-BD64-6E90EA1EE98BQ48192887-1A9D48D5-79D4-47AF-8D07-1639D2559297Q48526801-D67BD56D-4FEF-4E3E-A4DB-CD9EB2A3FDFEQ49485682-2F637FB1-5C4F-4F16-9722-BE3F80DEA60FQ52716912-7C918D95-3BD9-437D-914B-091B91BEB908Q52723685-7AF265DB-0AA1-45A4-ACB2-55B828ED76CAQ56890857-E4F02ADF-4C71-4676-B3DD-8AE656C258DEQ57165694-32152A03-A81F-48A5-AD0F-08515BC2B0A5Q57174193-165FCF16-51CD-4E40-888D-CB4788E238DFQ58610907-A05EE51F-7137-4537-B95C-C7DEBACACC69Q58726545-9F315B2D-B269-488B-B929-A7EA0633D6C2
P2860
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Blockade of the PD-1/PD-L1 axi ...... duced immune escape mechanism.
@en
Blockade of the PD-1/PD-L1 axi ...... duced immune escape mechanism.
@nl
type
label
Blockade of the PD-1/PD-L1 axi ...... duced immune escape mechanism.
@en
Blockade of the PD-1/PD-L1 axi ...... duced immune escape mechanism.
@nl
prefLabel
Blockade of the PD-1/PD-L1 axi ...... duced immune escape mechanism.
@en
Blockade of the PD-1/PD-L1 axi ...... duced immune escape mechanism.
@nl
P2093
P2860
P50
P356
P1433
P1476
Blockade of the PD-1/PD-L1 axi ...... nduced immune escape mechanism
@en
P2093
F S Lichtenegger
G Riethmüller
G Zugmaier
K Spiekermann
M Subklewe
P A Bauerle
P2860
P2888
P304
P356
10.1038/LEU.2015.214
P577
2015-08-04T00:00:00Z